Catalyst Wire Dossier Catalyst Wire Dossier

risperidone long-acting injectable (4-week formulation)

risperidone · Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Drug timelines are a Plus or Pro feature.

1 regulatory and trial event tracked for risperidone long-acting injectable (4-week formulation), covering 2014-05-21 to 2014-05-21. Get the full timeline:

Most recent: Clinical Trial Update: Characterization of Intramuscular Injections of Risperidone 4 Week Long-acting Injectable (LAI) Formulation in the Buttock of Patients With Schizophrenia [Phase 1]

See pricing